Premium
Fingolimod: new oral treatment for relapsing‐remitting MS
Author(s) -
Chaplin Steve,
Schmierer Klaus,
Farrell Rachel
Publication year - 2012
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.859
Subject(s) - fingolimod , medicine , multiple sclerosis , relapsing remitting , adverse effect , interferon beta , intensive care medicine , immunology
Fingolimod (Gilenya) is an oral disease‐modifying therapy licensed for relapsingremitting multiple sclerosis (RRMS) in patients with high disease activity despite treatment with an interferon beta. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse events, and Drs Klaus Schmierer and Rachel Farrell discuss its place in place in the treatment of RRMS. Copyright © 2012 Wiley Interface Ltd